NOVA Oncology

05/03/2026

Our site has a trial open for advances stage urinary bladder cancer, this trial offers state of the art drugs and precisely target the driving mutation.
This is provided with all costs of the drugs covered by the study.

05/03/2026

Dr Karim and her team offers a breast cancer clinical trial for patients with hormone receptor disease in the metastatic setting.
We are site #2 to find a patient eligible in the whole United States.
This trial offers state of art targeted therapy and provide access to population of cancer patients that has no access to trials otherwise.
Please call us to inquire 956-234-4400

09/26/2023

Any Patient with should ask their oncologist about their scans and tumor marker if applicable. If disease appears to be progressing, then ask your doctor to look for a phase I trial for you.

09/25/2023

https://www.youtube.com/watch?v=vn4eCX1kYXg&t=114s

Very interesting technology

A hallmark of cancer is the ability to avoid destruction by immune cells. Cancer cells develop escape mechanisms that can render them invisible to the human ...

09/24/2023

the Immunotherapy drug that now has over 18 approvals, was released to the market and became available to cancer patients from the phase I part of testing.

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease prog...

09/24/2023

.
Phase I trials provide an excellent option for patients who have no other options.
Contrary to the belief and the historic function of phase I studies as " toxicity studies" recent data suggest that the chances of achieving a response ( shrinkage of overall cancer size by >=30%) is now about 20% and it can even be higher if we choose the right molecular profile to 40%.

We encourage regular oncologist to look for a possible trial for their patients.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868302/

09/24/2023

a drug that target a rare genetic mutation in lung cancer was approved in 2014 from testing it on only 59 patients. It was approved from the phase I stage. Phase I part of drug testing is when the drug is first approved to be tried in human subjects after animal studies.

We want more approvals and more patients participate in those studies.

https://www.nejm.org/doi/full/10.1056/nejmoa1311107

09/24/2023

https://www.cancer.gov/news-events/cancer-currents-blog/2022/phase-1-cancer-clinical-trials-benefit-participants

NCI Published article speaking about the benefit of cancer patients. They are NOT a replacement for hospice and at the era of and and , they have the potential to induce tumor response and prolong and improve lives of cancer patients.
Response has doubled in the last decade compared to before and it is in the order of 10% and some patient enjoy a adorable remission and improved symptom burden. Fatality continued to be

NCI’s Dr. Naoko Takebe discusses the results of a new study showing that phase 1 cancer clinical trials benefit participants more than previously thought.

09/24/2023

Cancer research changes lives and improves survival and can touch the life of many others if a drug is tried and appears to be working.
We have plethora of new cancer therapies that are waiting to be examined in those patients in need.
Cancer Drugs can and will be approved form the initial phase of human testing- Phase I studies.
A living example is the approval of in with .

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.

https://pubmed.ncbi.nlm.nih.gov/34339292/Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Amivantamab, via its novel mechanism of action, yielded robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations after progression on platinum-based chemotherapy.

09/23/2023

It’s Urological Cancer Awareness Month – so let’s talk about bladder cancer.

Bladder cancer is a type of urological cancer. It is the 11th most common cancer in the UK. It begins when abnormal cells in the bladder lining start to grow and divide in an uncontrolled way.

The main symptom of bladder cancer is blood in your urine. Other symptoms may include problems peeing, unexplained weight loss, pain in your lower back, tummy or bones, or feeling tired and unwell.

If you see blood in your urine or notice anything unusual for you, talk to your doctor. In most cases it won’t be cancer – but if it is, catching it early can make all the difference.

Find out more 👉 https://cruk.ink/43Pl28h

09/23/2023

ABBV-514 is another Drug Brought by Abbvie now is being tried for lung cancer and head and neck cancer. It is a form of immunotherapy that targets a molecule called CCR8 which prevents the immune cells from fighting the cancer cells in the tumor mass.